Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
1.05 CAD 0.05 ( 5.00%)
Last update at 2026-11-04T18:39:00Z
VOLUME
605699
Market Cap
700.57M

Momentum Score

…

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.02
Low
1.06
High
52 Week Price Range
1.18
Low
3.28
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Canopy Growth Corp is a Canadian cannabis producer and consumer-packaged-goods company operating cultivation, processing and branded product lines with a strategic investment from Constellation Brands. Long-term growth drivers include expansion of legal recreational and medical markets, product diversification and international expansion, and recent restructuring that appears positioned to improve margins and cash generation.
Key risks include regulatory uncertainty (notably US federal legalization timing), intense competition and pricing pressure across markets, and execution and financing risk as the company seeks sustained profitability.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.00
Dividend Yield
-
Revenue TTM
278.39M
Revenue Per Share
1.16
Gross Profit TTM
73.94M
Debt / Equity
1.37
ROE
-48.50%
Net Debt
190.26M
ROCE
-63.46%
Diluted EPS TTM
-1.86

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -597.00M -471.36M -3314.32M -329.43M -1683.96M
Minority interest 0.00M 18.53M 31.39M 18.30M 140.01M
Net income -598.12M -657.27M -3278.16M -320.49M -1670.82M
Selling general administrative 60.85M 99.83M 449.12M 520.28M 666.54M
Selling and marketing expenses 60.85M 76.14M - 239.28M 194.40M
Gross profit 79.51M 80.88M -104.14M -193.05M 66.96M
Reconciled depreciation 43.12M 53.18M 84.52M 114.42M 127.12M
Ebit -522.43M -366.00M - -1082.67M 44.30M
Ebitda -479.31M -312.83M -507.04M -229.58M 171.42M
Depreciation and amortization 43.12M 53.18M - 853.10M 127.12M
Operating income -117.14M -228.71M -2845.30M -1082.67M 44.30M
Other operating expenses 386.14M 525.86M - 1233.66M 1146.23M
Interest expense 74.57M 105.35M 126.16M 103.94M 8.46M
Tax provision 7.14M 12.33M -4.77M -8.95M -13.14M
Interest income 464.50M 16.23M 507.61M 6.60M 478.10M
Net interest income -65.75M -89.12M -101.88M -97.34M 12.91M
Extraordinary items 6.02M -173.59M - - -
Income tax expense 7.14M 12.33M - -8.95M -13.14M
Total revenue 269.00M 297.15M 402.90M 520.33M 546.65M
Total operating expenses 196.65M 309.60M 994.46M 520.28M 666.54M
Cost of revenue 189.48M 216.26M 507.04M 713.38M 479.69M
Total other income expense net -479.85M -242.64M -2722.77M 753.24M -1728.26M
Net income from continuing ops -604.14M -483.68M -3309.55M -320.49M -1670.82M
Net income applicable to common shares -598.12M -657.27M -3278.16M -302.18M -1744.92M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 917.70M 1300.33M 2439.10M 5615.05M 6823.48M
Intangible assets 87.20M 104.05M 188.72M 252.69M 308.17M
Other current assets 2.03M 31.27M 23.61M 19.07M 19.07M
Total liab 430.49M 799.82M 1629.17M 1984.55M 3201.66M
Total stockholder equity 487.21M 500.37M 809.93M 3589.96M 3481.81M
Other current liab 15.34M 71.76M 94.73M 139.33M 207.24M
Common stock - 8244.30M 7938.57M 7482.81M 7168.56M
Capital stock 8796.41M 8244.30M 7938.57M 7482.81M 7168.56M
Retained earnings -10928.15M -10330.03M -7612.93M -6370.34M -6068.16M
Other liab - - - 178.84M 1250.03M
Good will 46.04M 43.24M 85.56M 1866.50M 1889.35M
Other assets - 0.00M 19.80M 479.52M 102.49M
Cash 113.81M 170.30M 462.46M 776.00M 1154.65M
Cash and equivalents - - 214.55M 305.32M 718.07M
Total current liabilities 94.40M 234.72M 803.84M 212.90M 284.33M
Current deferred revenue - - - - 100.81M
Net debt 190.26M 512.87M 629.87M 724.99M 428.31M
Short term debt - 134.28M 0.00M 9.30M 9.83M
Short long term debt 4.26M 103.94M 556.89M 9.30M 9.83M
Short long term debt total - 683.17M - 1500.99M 1582.96M
Other stockholder equity - 2602.15M -13.86M 2519.77M 2415.65M
Property plant equipment - - 499.47M 942.78M 1074.54M
Total current assets 294.57M 371.18M 1077.25M 1737.40M 2838.19M
Long term investments 35.29M 136.22M 568.29M 341.73M 708.27M
Net tangible assets - - - 1470.76M 1284.29M
Short term investments 17.66M 40.47M 105.59M 595.65M 1144.56M
Net receivables 47.51M 51.85M 93.99M 96.44M 92.44M
Long term debt 299.81M 493.29M 749.99M 1491.69M 1573.14M
Inventory 96.37M 77.29M 148.90M 204.39M 367.98M
Accounts payable 26.10M 28.67M 76.23M 64.27M 67.26M
Accumulated other comprehensive income - -16.05M - -42.28M -34.24M
Non currrent assets other 16.39M -79.93M 19.80M 15.34M 4.96M
Non current assets total 623.13M 929.15M 1361.84M 3877.65M 3985.29M
Capital lease obligations 44.33M 70.77M 109.31M 139.16M 136.22M
Long term debt total - - 789.64M 1534.79M 1605.02M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -47.79M 241.59M 433.38M 166.58M -497.56M
Change to liabilities - - - -35.84M 16.54M
Total cashflows from investing activities -47.79M 241.59M 433.38M 230.82M -884.11M
Net borrowings -220.78M -509.78M - -50.76M 877.54M
Total cash from financing activities 148.66M -465.06M -19.69M -45.53M 1264.77M
Change to operating activities - - - 24.47M 0.08M
Net income -604.14M -483.68M -3309.55M -320.49M -1670.82M
Change in cash -56.49M -506.71M -99.00M -378.65M -148.52M
Begin period cash flow 170.30M 677.01M 776.00M 1154.65M 1303.18M
End period cash flow 113.81M 170.30M 677.01M 776.00M 1154.65M
Total cash from operating activities -165.75M -281.95M -557.55M -545.81M -465.73M
Issuance of capital stock 385.39M 81.06M 1.05M 2.70M 1.38M
Depreciation 43.12M 53.18M 56.74M 114.42M 127.12M
Other cashflows from investing activities 48.90M 167.38M 443.93M -18.13M -56.87M
Change to inventory -17.71M 1.03M 55.64M 173.19M 17.21M
Change to account receivables -4.49M -3.75M - 3.74M -11.99M
Sale purchase of stock 393.96M 81.06M 1.33M 8.27M 403.46M
Other cashflows from financing activities -15.96M -36.34M -38.01M 2.53M 1279.01M
Change to netincome - - - -523.61M 1124.34M
Capital expenditures 11.28M 4.00M 10.55M 48.11M 174.14M
Change in working capital -31.96M -38.69M 59.25M 165.56M -4.33M
Stock based compensation -4.21M 14.18M 31.19M 47.52M 91.15M
Other non cash items 424.30M 160.74M -6.59M -543.88M 1004.30M
Free cash flow -177.03M -285.95M -568.10M -593.92M -639.87M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
WEED
Canopy Growth Corp
0.05
5.00%
1.05 - 20.49 2.52 0.87 1.95 -1.50
CURA
Curaleaf Holdings Inc.
-0.65
4.57%
13.58 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc
0.32
2.80%
11.73 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc
0.20
4.20%
4.96 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc
0.45
12.10%
4.17 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Canopy Growth Corp

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

1 Hershey Drive, Smiths Falls, ON, Canada, K7A 0A8

855 558 9333

960

Name Title Year Born
Mr. David Eric Klein CEO & Director 1964
Ms. Judy Eunjoo Hong VP of Investor Relations & Competitive Intelligence, Chief of Staff to the CEO and CFO 1973
Mr. Julious C. Grant Jr. Chief Commercial Officer 1968
Mr. Jonathan Di Tosto Chief Operations Officer NA
Mr. Thomas Carlton Stewart VP & Chief Accounting Officer 1982
Mr. Thomas Shipley IV Sr. VP of Quality Assurance & Chief Science Officer 1989
Dr. Christelle Gedeon L.L.B., Ph.D. Chief Legal Officer 1982
Mr. Timothy Rob Saunders F.C.A., FCPA Strategic Advisor 1961
Jason Green Head of Agriculture - Hemp Division NA
Dr. Mark A. Ware Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…